Loading…
ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION
Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacteria...
Saved in:
Published in: | Journal of antibiotics 1986, Vol.39(5), pp.660-668 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353 |
---|---|
cites | |
container_end_page | 668 |
container_issue | 5 |
container_start_page | 660 |
container_title | Journal of antibiotics |
container_volume | 39 |
creator | CHANTOT, JEAN-FRANÇOIS BRYSKIER, ANDRÉ GASC, JEAN-CLAUDE |
description | Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs. |
doi_str_mv | 10.7164/antibiotics.39.660 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76955481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76955481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</originalsourceid><addsrcrecordid>eNpNkF1LwzAUhoMoOj_-gCD0QrzrTJo0TbwyjqnFukKp4q5CkiVa6T5sugv_vRkbw5tzDrzPOe_hBeASwWGGKLlVi77RzbJvjB9iPqQUHoABYgzFiFB-CAYQJihmLIEn4NT7bwhxhjN2DI5DxylKB-BeTOr8QYzqcZWLIgpD_p7X06h8jKryI6-fq_J1Osond5GICvFQVqIuq2k0fhfFm6jzcnIOjpxqvb3Y9TPw9jiuR89xUT7lI1HEhia8j4mmxGnIqcV2ZjiHDhnNqHOaJYl2iUEEKsqJhgzPNGEzToxy3KbWIJbgFJ-Bm-3dVbf8WVvfy3njjW1btbDLtZcZ5WlKGApgsgVNt_S-s06uumauul-JoNzEJv_FJjGXIbawdLW7vtZzO9uv7HIK-vVOV96o1nVqYRq_x9gGg1nAXrbYt-_Vp93rqgtmrf3vjDhlG_d0W8ITe8p8qU7aBf4D38SOWA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76955481</pqid></control><display><type>article</type><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><source>JSTAGE</source><creator>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</creator><creatorcontrib>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</creatorcontrib><description>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</description><identifier>ISSN: 0021-8820</identifier><identifier>EISSN: 1881-1469</identifier><identifier>DOI: 10.7164/antibiotics.39.660</identifier><identifier>PMID: 3733515</identifier><identifier>CODEN: JANTAJ</identifier><language>eng</language><publisher>Tokyo: JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</publisher><subject>Animals ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Erythromycin - metabolism ; Erythromycin - pharmacology ; Kinetics ; Leucomycins - metabolism ; Leucomycins - pharmacology ; Male ; Medical sciences ; Mice ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Rats ; Tissue Distribution</subject><ispartof>The Journal of Antibiotics, 1986, Vol.39(5), pp.660-668</ispartof><rights>Japan Antibiotics Research Association</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1882,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8733507$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3733515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHANTOT, JEAN-FRANÇOIS</creatorcontrib><creatorcontrib>BRYSKIER, ANDRÉ</creatorcontrib><creatorcontrib>GASC, JEAN-CLAUDE</creatorcontrib><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><title>Journal of antibiotics</title><addtitle>J. Antibiot.</addtitle><description>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</description><subject>Animals</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Erythromycin - metabolism</subject><subject>Erythromycin - pharmacology</subject><subject>Kinetics</subject><subject>Leucomycins - metabolism</subject><subject>Leucomycins - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Tissue Distribution</subject><issn>0021-8820</issn><issn>1881-1469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpNkF1LwzAUhoMoOj_-gCD0QrzrTJo0TbwyjqnFukKp4q5CkiVa6T5sugv_vRkbw5tzDrzPOe_hBeASwWGGKLlVi77RzbJvjB9iPqQUHoABYgzFiFB-CAYQJihmLIEn4NT7bwhxhjN2DI5DxylKB-BeTOr8QYzqcZWLIgpD_p7X06h8jKryI6-fq_J1Osond5GICvFQVqIuq2k0fhfFm6jzcnIOjpxqvb3Y9TPw9jiuR89xUT7lI1HEhia8j4mmxGnIqcV2ZjiHDhnNqHOaJYl2iUEEKsqJhgzPNGEzToxy3KbWIJbgFJ-Bm-3dVbf8WVvfy3njjW1btbDLtZcZ5WlKGApgsgVNt_S-s06uumauul-JoNzEJv_FJjGXIbawdLW7vtZzO9uv7HIK-vVOV96o1nVqYRq_x9gGg1nAXrbYt-_Vp93rqgtmrf3vjDhlG_d0W8ITe8p8qU7aBf4D38SOWA</recordid><startdate>1986</startdate><enddate>1986</enddate><creator>CHANTOT, JEAN-FRANÇOIS</creator><creator>BRYSKIER, ANDRÉ</creator><creator>GASC, JEAN-CLAUDE</creator><general>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</general><general>Japan Antibiotics Research Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1986</creationdate><title>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</title><author>CHANTOT, JEAN-FRANÇOIS ; BRYSKIER, ANDRÉ ; GASC, JEAN-CLAUDE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Animals</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Erythromycin - metabolism</topic><topic>Erythromycin - pharmacology</topic><topic>Kinetics</topic><topic>Leucomycins - metabolism</topic><topic>Leucomycins - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Tissue Distribution</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHANTOT, JEAN-FRANÇOIS</creatorcontrib><creatorcontrib>BRYSKIER, ANDRÉ</creatorcontrib><creatorcontrib>GASC, JEAN-CLAUDE</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHANTOT, JEAN-FRANÇOIS</au><au>BRYSKIER, ANDRÉ</au><au>GASC, JEAN-CLAUDE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION</atitle><jtitle>Journal of antibiotics</jtitle><addtitle>J. Antibiot.</addtitle><date>1986</date><risdate>1986</risdate><volume>39</volume><issue>5</issue><spage>660</spage><epage>668</epage><pages>660-668</pages><issn>0021-8820</issn><eissn>1881-1469</eissn><coden>JANTAJ</coden><abstract>Roxithromycin, formerly known as RU 28965 (9-[O[(2-methoxyethoxy)methyl]oxime]-erythromycin), is a novel 14 atom-membered semisynthetic macrolide with an antibacterial spectrum directed towards Gram-positive cocci and bacilli, Gram-negative cocci and some Parvobacteriaceae. The in vitro antibacterial activity of roxithromycin was compared with those of erythromycin and spiramycin against 275 clinical isolates by using 2-fold broth macro-dilution tests. The antibacterial spectrum of roxithromycin and erythromycin were qualitatively comparable (including the bacteriostatic type of activity and the profile of resistance), but minimal inhibitory concentrations of erythromycin were generally one half those of roxithromycin, except for Corynebacterium sp. and Bacteroides fragilis against which the new macrolide was more active. On the other hand, roxithromycin exhibited a superior in vivo antibacterial activity in laboratory animals, being up to six times more potent than erythromycin in curing experimentally infected mice. Roxithromycin showed high blood levels and long half-lives of elimination in rodents after oral administration, and its bioavailability amounted to 72% in mice and 85% in rats, compared to less than 10% for erythromycin. Roxithromycin was widely distributed throughout the body with a high degree of penetration into all tissues, particularly in the lungs.</abstract><cop>Tokyo</cop><pub>JAPAN ANTIBIOTICS RESEARCH ASSOCIATION</pub><pmid>3733515</pmid><doi>10.7164/antibiotics.39.660</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-8820 |
ispartof | The Journal of Antibiotics, 1986, Vol.39(5), pp.660-668 |
issn | 0021-8820 1881-1469 |
language | eng |
recordid | cdi_proquest_miscellaneous_76955481 |
source | JSTAGE |
subjects | Animals Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Erythromycin - metabolism Erythromycin - pharmacology Kinetics Leucomycins - metabolism Leucomycins - pharmacology Male Medical sciences Mice Microbial Sensitivity Tests Pharmacology. Drug treatments Rats Tissue Distribution |
title | ANTIBACTERIAL ACTIVITY OF ROXITHROMYCIN: A LABORATORY EVALUATION |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A31%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ANTIBACTERIAL%20ACTIVITY%20OF%20ROXITHROMYCIN:%20A%20LABORATORY%20EVALUATION&rft.jtitle=Journal%20of%20antibiotics&rft.au=CHANTOT,%20JEAN-FRAN%C3%87OIS&rft.date=1986&rft.volume=39&rft.issue=5&rft.spage=660&rft.epage=668&rft.pages=660-668&rft.issn=0021-8820&rft.eissn=1881-1469&rft.coden=JANTAJ&rft_id=info:doi/10.7164/antibiotics.39.660&rft_dat=%3Cproquest_cross%3E76955481%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c629t-4b64fb096e3edc990f1cb86ffb822bf2c140a694b083db48d94caf9e5ec182353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76955481&rft_id=info:pmid/3733515&rfr_iscdi=true |